183 related articles for article (PubMed ID: 38806724)
1. PARP inhibition leads to synthetic lethality with key splicing-factor mutations in myelodysplastic syndromes.
Zhang F; Sun J; Zhang L; Li R; Wang Y; Geng H; Shen C; Li L; Chen L
Br J Cancer; 2024 May; ():. PubMed ID: 38806724
[TBL] [Abstract][Full Text] [Related]
2. Physiological
Kon A; Yamazaki S; Nannya Y; Kataoka K; Ota Y; Nakagawa MM; Yoshida K; Shiozawa Y; Morita M; Yoshizato T; Sanada M; Nakayama M; Koseki H; Nakauchi H; Ogawa S
Blood; 2018 Feb; 131(6):621-635. PubMed ID: 29146882
[TBL] [Abstract][Full Text] [Related]
3.
Smeets MF; Tan SY; Xu JJ; Anande G; Unnikrishnan A; Chalk AM; Taylor SR; Pimanda JE; Wall M; Purton LE; Walkley CR
Blood; 2018 Aug; 132(6):608-621. PubMed ID: 29903888
[TBL] [Abstract][Full Text] [Related]
4. R-Loop Accumulation in Spliceosome Mutant Leukemias Confers Sensitivity to PARP1 Inhibition by Triggering Transcription-Replication Conflicts.
Liu ZS; Sinha S; Bannister M; Song A; Arriaga-Gomez E; McKeeken AJ; Bonner EA; Hanson BK; Sarchi M; Takashima K; Zong D; Corral VM; Nguyen E; Yoo J; Chiraphapphaiboon W; Leibson C; McMahon MC; Rai S; Swisher EM; Sachs Z; Chatla S; Stirewalt DL; Deeg HJ; Skorski T; Papapetrou EP; Walter MJ; Graubert TA; Doulatov S; Lee SC; Nguyen HD
Cancer Res; 2024 Feb; 84(4):577-597. PubMed ID: 37967363
[TBL] [Abstract][Full Text] [Related]
5. SRSF2 Is Essential for Hematopoiesis, and Its Myelodysplastic Syndrome-Related Mutations Dysregulate Alternative Pre-mRNA Splicing.
Komeno Y; Huang YJ; Qiu J; Lin L; Xu Y; Zhou Y; Chen L; Monterroza DD; Li H; DeKelver RC; Yan M; Fu XD; Zhang DE
Mol Cell Biol; 2015 Sep; 35(17):3071-82. PubMed ID: 26124281
[TBL] [Abstract][Full Text] [Related]
6. Inhibitors of poly ADP-ribose polymerase (PARP) induce apoptosis of myeloid leukemic cells: potential for therapy of myeloid leukemia and myelodysplastic syndromes.
Gaymes TJ; Shall S; MacPherson LJ; Twine NA; Lea NC; Farzaneh F; Mufti GJ
Haematologica; 2009 May; 94(5):638-46. PubMed ID: 19407318
[TBL] [Abstract][Full Text] [Related]
7. Modulation of splicing catalysis for therapeutic targeting of leukemia with mutations in genes encoding spliceosomal proteins.
Lee SC; Dvinge H; Kim E; Cho H; Micol JB; Chung YR; Durham BH; Yoshimi A; Kim YJ; Thomas M; Lobry C; Chen CW; Pastore A; Taylor J; Wang X; Krivtsov A; Armstrong SA; Palacino J; Buonamici S; Smith PG; Bradley RK; Abdel-Wahab O
Nat Med; 2016 Jun; 22(6):672-8. PubMed ID: 27135740
[TBL] [Abstract][Full Text] [Related]
8. Replication stress signaling is a therapeutic target in myelodysplastic syndromes with splicing factor mutations.
Flach J; Jann JC; Knaflic A; Riabov V; Streuer A; Altrock E; Xu Q; Schmitt N; Obländer J; Nowak V; Danner J; Mehralivand A; Hofmann F; Palme I; Jawhar A; Wuchter P; Metzgeroth G; Nolte F; Hofmann WK; Nowak D
Haematologica; 2021 Nov; 106(11):2906-2917. PubMed ID: 33054116
[TBL] [Abstract][Full Text] [Related]
9. Myelodysplastic Syndrome-Associated SRSF2 Mutations Cause Splicing Changes by Altering Binding Motif Sequences.
Masaki S; Ikeda S; Hata A; Shiozawa Y; Kon A; Ogawa S; Suzuki K; Hakuno F; Takahashi SI; Kataoka N
Front Genet; 2019; 10():338. PubMed ID: 31040863
[TBL] [Abstract][Full Text] [Related]
10. A mitochondrial surveillance mechanism activated by
Liu X; Devadiga SA; Stanley RF; Morrow R; Janssen K; Quesnel-Vallières M; Pomp O; Moverley AA; Li C; Skuli N; Carroll MP; Huang J; Wallace DC; Lynch KW; Abdel-Wahab O; Klein PS
bioRxiv; 2024 Apr; ():. PubMed ID: 38712254
[TBL] [Abstract][Full Text] [Related]
11. Disease-associated mutation in SRSF2 misregulates splicing by altering RNA-binding affinities.
Zhang J; Lieu YK; Ali AM; Penson A; Reggio KS; Rabadan R; Raza A; Mukherjee S; Manley JL
Proc Natl Acad Sci U S A; 2015 Aug; 112(34):E4726-34. PubMed ID: 26261309
[TBL] [Abstract][Full Text] [Related]
12. Myelodysplastic syndrome and acute myeloid leukaemia in patients treated with PARP inhibitors: a safety meta-analysis of randomised controlled trials and a retrospective study of the WHO pharmacovigilance database.
Morice PM; Leary A; Dolladille C; Chrétien B; Poulain L; González-Martín A; Moore K; O'Reilly EM; Ray-Coquard I; Alexandre J
Lancet Haematol; 2021 Feb; 8(2):e122-e134. PubMed ID: 33347814
[TBL] [Abstract][Full Text] [Related]
13. Transcriptomic rationale for synthetic lethality-targeting ERCC1 and CDKN1A in chronic myelomonocytic leukaemia.
Hurtado AM; Luengo-Gil G; Chen-Liang TH; Amaral F; Batta K; Palomo L; Lumbreras E; Przychodzen B; Caparros E; Amigo ML; Dıez-Campelo M; Zamora L; Salido Fierrez EJ; Maciejewski JP; Ortuño FJ; Vicente V; Del Canizo M; Sole F; Ferrer-Marin F; Wiseman DH; Jerez A
Br J Haematol; 2018 Aug; 182(3):373-383. PubMed ID: 29797327
[TBL] [Abstract][Full Text] [Related]
14. Splicing factor mutant myelodysplastic syndromes: Recent advances.
Pellagatti A; Boultwood J
Adv Biol Regul; 2020 Jan; 75():100655. PubMed ID: 31558432
[TBL] [Abstract][Full Text] [Related]
15. [RNA splicing dysregulation in hematological malignancies].
Yoshida M; Yamauchi H; Sakumoto M; Yoshimi A
Rinsho Ketsueki; 2023; 64(7):646-653. PubMed ID: 37544725
[TBL] [Abstract][Full Text] [Related]
16. RUNX1 deficiency cooperates with SRSF2 mutation to induce multilineage hematopoietic defects characteristic of MDS.
Huang YJ; Chen JY; Yan M; Davis AG; Miyauchi S; Chen L; Hao Y; Katz S; Bejar R; Abdel-Wahab O; Fu XD; Zhang DE
Blood Adv; 2022 Dec; 6(23):6078-6092. PubMed ID: 36206200
[TBL] [Abstract][Full Text] [Related]
17. Myelodysplasia-associated mutations in serine/arginine-rich splicing factor SRSF2 lead to alternative splicing of CDC25C.
Skrdlant L; Stark JM; Lin RJ
BMC Mol Biol; 2016 Aug; 17(1):18. PubMed ID: 27552991
[TBL] [Abstract][Full Text] [Related]
18. SRSF2 mutations drive oncogenesis by activating a global program of aberrant alternative splicing in hematopoietic cells.
Liang Y; Tebaldi T; Rejeski K; Joshi P; Stefani G; Taylor A; Song Y; Vasic R; Maziarz J; Balasubramanian K; Ardasheva A; Ding A; Quattrone A; Halene S
Leukemia; 2018 Dec; 32(12):2659-2671. PubMed ID: 29858584
[TBL] [Abstract][Full Text] [Related]
19. Microsatellite instability induced mutations in DNA repair genes CtIP and MRE11 confer hypersensitivity to poly (ADP-ribose) polymerase inhibitors in myeloid malignancies.
Gaymes TJ; Mohamedali AM; Patterson M; Matto N; Smith A; Kulasekararaj A; Chelliah R; Curtin N; Farzaneh F; Shall S; Mufti GJ
Haematologica; 2013 Sep; 98(9):1397-406. PubMed ID: 23349304
[TBL] [Abstract][Full Text] [Related]
20. The Augmented R-Loop Is a Unifying Mechanism for Myelodysplastic Syndromes Induced by High-Risk Splicing Factor Mutations.
Chen L; Chen JY; Huang YJ; Gu Y; Qiu J; Qian H; Shao C; Zhang X; Hu J; Li H; He S; Zhou Y; Abdel-Wahab O; Zhang DE; Fu XD
Mol Cell; 2018 Feb; 69(3):412-425.e6. PubMed ID: 29395063
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
